AADI BIOSCIENCE INC NASDAQ:AADI Aadi is a clinical stage biopharmaceutical company developing precision therapies for genomically defined cancers. Aadi’s primary goal is to bring transformational outcomes to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety or effective targeting to the disease site. Aadi’s initial focus is on treating patients with aberrant TSC1 or TSC2 genes, tumor suppressors that when mutated are the source of many different cancer types. Aadi’s AMPECT pivotal trial of ABI-009 demonstrated meaningful clinical efficacy in Malignant PEComa, a type of cancer with the highest known mutation rate of TSC1 or TSC2 genes. Based on the AMPECT trial, emerging data for ABI-009 in other solid tumors with TSC1 or TSC2 mutations, and following discussions with the FDA, Aadi is proceeding with a tumor-agnostic registrational trial in cancers harboring TSC1 or TSC2 pathogenic, inactivating mutations with a planned initiation in 2021. Aadi also has ongoing studies across multiple high unmet need, advanced cancers including colorectal cancer, sarcoma, and glioblastoma to identify activity of ABI-009 in additional mTOR pathway driver alterations and combination regimens.

Location: 9987 Carver Rd, Ohio, 45242-5550, US | Website: aadibio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing